Oropharyngeal Cancer

A blood test to detect circulating tumor DNA accurately predicted recurrence of HPV-driven oropharyngeal cancer after treatment, according to research presented at Multidisciplinary Head and Neck Cancers Symposium.

Oropharyngeal cancer incidence and mortality have increased steadily among men in the United States during the past 2 decades, according to study results published in JAMA Otolaryngology-Head & Neck Surgery.

Men are significantly more likely than women to have oral HPV infection, regardless of vaccination status, according to a study in Clinical Infectious Diseases.

April is Head and Neck Cancer Awareness Month.

The FDA cleared an investigational new drug application for the combination of AFM24 and SNK-01 in patients with solid tumors that express epidermal growth factor receptor, according to a joint press release from each agent’s manufacturer.

Once the leading cause of cancer death among U.S. women, cervical cancer incidence and mortality have decreased substantially over the past 40 years, largely due to screening.

Transoral robotic surgery appeared associated with improved surgical and long-term survival outcomes compared with nonrobotic surgery for patients with early-stage oropharyngeal cancer, according to study results published in JAMA Oncology.

Transoral resection followed by low-dose radiation appeared safe and effective for patients with p16-positive oropharynx cancer, according to results of a randomized phase 2 trial presented during the ASCO20 Virtual Scientific Program.

The NCI awarded a 5-year, $8.3 million research grant to Weill Cornell Medicine, Moffitt Cancer Center and Universidade de Sao Paulo in Brazil to investigate strategies to prevent HPV-related cancers among individuals with HIV.

Rates of late-stage head and neck cancer increased in the United States between 2004 and 2015, propelled by rising incidence among white men, according to study results published in Cancer.